Clinical trials · Arkansas
Schizophrenia clinical trials in Arkansas
We’re tracking 21 recruiting schizophrenia studies with a site in Arkansas — including Phase 1, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Arkansas
- NCT07459647RecruitingPhase 2
Long-term study of ML-007C-MA for schizophrenia
This trial tests a new drug, ML-007C-MA, for adults with schizophrenia who may benefit from ongoing treatment. It aims to see how safe and effective the drug is over a longer period.
Little Rock, ArkansasAges 18–65 - NCT07410507RecruitingPhase 2
Study of Brenipatide for adults with schizophrenia
This trial tests an investigational drug called brenipatide for people with schizophrenia who are already on a stable medication regimen. The goal is to see if adding this drug helps reduce relapses.
Little Rock, ArkansasAges 18–55 - NCT07734493RecruitingPhase 1
Study of a new drug for acute schizophrenia symptoms
This trial tests an experimental medicine, LTX-001, for people with schizophrenia who are currently having a sudden worsening of symptoms. It aims to see if the drug can help reduce these acute symptoms.
Little Rock, ArkansasAges 18–55 - NCT07467993RecruitingPhase 2
Testing GXV813 for hospitalized adults with schizophrenia
This trial tests a new drug, GXV813, to see if it helps reduce symptoms in people with schizophrenia who are currently hospitalized due to a sudden worsening of their condition. It compares the drug's safety and effect against a placebo over several weeks.
Bentonville, ArkansasAges 18–65 - NCT07680946RecruitingPhase 2
Testing ublituximab for treatment-resistant schizophrenia
This trial tests an experimental drug, ublituximab, to see if it helps people with schizophrenia that hasn't gotten better with standard treatments. It may offer a new option for those who still have significant symptoms despite current therapy.
Little Rock, ArkansasAges 18–60 - NCT05184335RecruitingPhase 3
Brilaroxazine for adults with schizophrenia
This study tests whether brilaroxazine works and is safe for people with schizophrenia. It mainly aims to help people whose symptoms are still present despite prior treatment, while excluding those with certain other diagnoses or substance/drug issues.
Bentonville, ArkansasAges 18–65 - NCT05303064RecruitingPhase 3
Study of weight gain medicine for teens with certain mood or psychosis
This Phase 3 study tests a treatment aimed at reducing unhealthy weight gain in teens with schizophrenia or bipolar I disorder, using changes in BMI (a height-and-weight measure). It may help families who are concerned about weight changes that can happen with some psychiatric medicines.
Little Rock, ArkansasAges 10–17 - NCT06229210RecruitingPhase 3
Lumateperone safety study for children with schizophrenia, bipolar, or autism
This trial tests a medication called lumateperone for children and teens with schizophrenia, bipolar disorder, or autism spectrum disorder. It aims to see if the medicine is safe and tolerable over time.
Little Rock, ArkansasAges 5–17 - NCT06894212RecruitingPhase 3
Testing a new med for schizophrenia flare-ups
This trial tests a new medication called SEP-363856 for people with schizophrenia who are currently having a severe flare-up of symptoms. It aims to see if the drug is safe and effective compared to a placebo.
Bentonville, ArkansasAges 18–65 - NCT06961968RecruitingPhase 3
Schizophrenia medication withdrawal study
This study tests whether patients with schizophrenia can safely stop or reduce their current medication without worsening symptoms. It is designed for people who need ongoing psychiatric care.
Rogers, ArkansasAges 18–65 - NCT06963034RecruitingPhase 3
Study of a new medicine for adults with schizophrenia
This trial tests an investigational medicine called NBI-1117568 in adults with schizophrenia who are currently having a relapse or worsening of symptoms and need to stay in the hospital. The goal is to see if the medicine is safe and effective.
Bryant, ArkansasAges 18–65 - NCT07114874RecruitingPhase 3
A long-term study of a new drug for schizophrenia
This study tests a new medicine called NBI-1117568 for adults with schizophrenia over a longer period of time. Participants will stop their current antipsychotics and take this new drug to see how well it works and how safe it is.
Bryant, ArkansasAges 18–65 - NCT07145918RecruitingPhase 2
Study of an oral schizophrenia drug for adults
This trial tests an experimental oral drug (emraclidine) to see if it helps symptoms of schizophrenia and how it moves through the body. It looks at two groups of participants: those with stable symptoms and those having an acute flare-up.
Little Rock, ArkansasAges 18–65 - NCT07191483RecruitingPhase 2
Study of KYN-5356 for cognitive problems in schizophrenia
This trial tests an investigational drug, KYN-5356, to see if it can improve thinking and memory problems in adults with schizophrenia. You may join if your schizophrenia is stable and you take only one antipsychotic medication.
Little Rock, ArkansasAges 18–55 - NCT07363577RecruitingPhase 3
Testing LB-102 for adults with acute schizophrenia
This trial tests a new medication called LB-102 for people with acute (sudden worsening of) schizophrenia. It aims to see if the drug helps reduce symptoms like hallucinations or disorganized thinking.
Bentonville, ArkansasAges 18–65 - NCT07379827Recruiting
A study on switching to KarXT for schizophrenia
This trial looks at how well KarXT works and what side effects it might have when people with schizophrenia switch to it from their current antipsychotic medication. It may be an option for those who have started KarXT recently or who plan to switch from their current treatment.
Bryant, ArkansasAges 18 years+ - NCT07369154RecruitingPhase 3
Safety of a long-term schizophrenia treatment
This study tests the long-term safety of an investigational medication for schizophrenia over one year. It may be an option if you are currently stable on your antipsychotic medication.
Bentonville, ArkansasAges 18–65 - NCT05648591RecruitingPhase 4
Iloperidone study for teens with schizophrenia or bipolar I
This Phase 4 study checks how safe and well-tolerated iloperidone is when used in a typical, open-label way for teenagers. It may help doctors better understand side effects and safety in teens with schizophrenia or bipolar I disorder.
Little Rock, ArkansasAges 12–17 - NCT07105111RecruitingPhase 4
Valbenazine for tardive dyskinesia after other treatment
This study tests if valbenazine helps adults with tardive dyskinesia whose symptoms continue even after taking or stopping another similar medication. Tardive dyskinesia involves uncontrollable movements from long-term use of certain mental health drugs.
Bryant, ArkansasAges 18 years+ - NCT07221877RecruitingPhase 4
Study of KarXT for urological safety in schizophrenia
This study tests a new medicine (KarXT) for schizophrenia, focusing on how it affects urological (bladder and urinary) safety. You'll stop your current antipsychotic and take the study drug to see if it works well and is safe for your urinary system.
Little Rock, ArkansasAges 18–65 - NCT04987229Enrolling by invitationPhase 3
Kid’s long-term safety follow-up for OLZ and SAM treatment
This study checks how safe a kid’s ongoing treatment is over a longer period. It is mainly for children who already finished a related study and may benefit from continuing the same medicines.
Little Rock, ArkansasAges 10–17
Where these studies are running in Arkansas
Institutions with a site for the recruiting schizophrenia studies listed above.
- Pillar Clinical Research · 8 studies
- Woodland International Research Group · 5 studies
- Neurocrine Clinical Site · 4 studies
- Alkermes · 2 studies
- Vanda Investigational Site · 2 studies
- Clinical Site
- Reviva site
- SanRo Clinical Research Group
What taking part in a schizophrenia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Schizophrenia trials in other states
Common questions
- Are there schizophrenia clinical trials in Arkansas?
- Yes. We're currently tracking 21 recruiting schizophrenia studies with a site in Arkansas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a schizophrenia study in Arkansas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Arkansas to take part?
- Not necessarily. These studies have a site in Arkansas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a schizophrenia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New schizophrenia studies open in Arkansas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.